<PAGE>
Page 1 of 4 Pages
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
SCHEDULE 13D
Under the Securities Exchange Act of 1934
(Amendment No. 1)
Angeion Corporation
(Name of Issuer)
Common Stock, par value $.01 per share
(Title of Class of Securities)
03462H 10 7
(CUSIP Number)
James C. Colihan, Esq.
Coudert Brothers
1114 Avenue of the Americas
New York, NY 10036 (212) 626-4400
(Name, Address and Telephone Number of Person
Authorized to Receive Notices and Communications)
Not Applicable
(Date of Event which Requires
Filing of this Statement)
If the filing person has previously filed a statement on Schedule 13G to
report the acquisition that is the subject of this Schedule 13D, and is filing
this schedule because of Sections 240.13d-1(e), 240.13d-1(f) or 240.13d-1(g),
check the following box |_|.
<PAGE>
Page 2 of 4 Pages
This Amendment No. 1 to the Schedule 13D, dated December 19, 1997
(the "Schedule 13D"), filed by Synthelabo with the Securities and Exchange
Commission with respect to the Common Stock, par value $.01 per share, of
Angeion Corporation, is being filed to amend Item 7 (Materials to Be Filed as
Exhibits) of the Schedule 13D to amend and add to the Exhibits being
incorporated by reference therein.
Item 7 of the Schedule 13D is hereby amended to read in its entirety
as follows:
Item 7. Materials to Be Filed as Exhibits.
1. Amended and Restated Investment and Master Strategic
Relationship Agreement between Synthelabo and Angeion
Corporation, dated as of October 9, 1997, together with
Exhibits A-1, A-2, A-3, A-4, A-5, B, C, D, G and H thereto and
Side Letter between Angeion Corporation and Synthelabo dated
as of December 9, 1997.
The foregoing Exhibits are incorporated herein by reference to
Exhibits 10.1, 10.7, 10.8, 10.9, 10.10, 10.11, 10.3, 10.2,
10.4, 10.5, 10.6 and 10.14, respectively, filed as part of
Angeion Corporation's Form 10-Q/A to its Quarterly Report on
Form 10-Q for the quarterly period ended October 31, 1997,
which Form 10-Q/A was filed with the Securities and Exchange
Commission on July 29, 1998.
[remainder of page intentionally blank]
<PAGE>
Page 3 of 4 Pages
SIGNATURE
After reasonable inquiry and to the best of my knowledge and belief,
the undersigned certifies that the information set forth in this statement is
true, complete and correct.
Dated: July 30, 1998
SYNTHELABO
By: /s/ Pierre Lepienne
Name: Pierre Lepienne
Title: Executive Vice President
Member of the Board
<PAGE>
Page 4 of 4 Pages
EXHIBIT INDEX
<TABLE>
<CAPTION>
Exhibit Page Number
- ------ -----------
<S> <C>
1. Amended and Restated Investment and Master Incorporated by reference to
Strategic Relationship Agreement, between Exhibits 10.1, 10.7, 10.8,
Synthelabo and Angeion Corporation, dated as 10.9, 10.10, 10.11, 10.3,
of October 9, 1997, together with Exhibits 10.2, 10.4, 10.5, 10.6 and
A-1, A-2, A-3, A-4, A-5, B, C, D, G and H 10.14, respectively, to Angeion
thereto and Side Letter between Angeion Corporation's Form 10-Q/A to its
Corporation and Synthelabo dated as of Quarterly Report on Form 10-Q for
December 9, 1997.* the quartelry period ended October
31, 1997, which Form 10-Q/A was
filed with the Securities and
Exchange Commission on July 29, 1998.
</TABLE>
- ------------------------
* Portions of certain of the exhibits have been omitted, as indicated
therein, pursuant to requests for confidential treatment by Angeion
Corporation and Synthelabo.
